Clinical Trial Update: Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating TAK-659 in combination with Ixazomib for relapsed/refractory acute myeloid leukemia; study status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• TAK-659 (TAK-659)
• ixazomib (ixazomib)

Snippet

Sponsor: H Scott Boswell | Conditions: AML, AML, Adult | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-09-13